Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 157Lung Neoplasms 73Carcinoma, Hepatocellular 63Small Cell Lung Carcinoma 52Breast Neoplasms 47Squamous Cell Carcinoma of Head and Neck 36Urinary Bladder Neoplasms 30Colorectal Neoplasms 30Neoplasms 29Biliary Tract Neoplasms 29Neoplasm Metastasis 28Cholangiocarcinoma 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Ovarian Neoplasms 24Head and Neck Neoplasms 19Liver Neoplasms 18Carcinoma, Renal Cell 17Recurrence 16Melanoma 15Stomach Neoplasms 13Prostatic Neoplasms 13Carcinoma 13Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Esophageal Neoplasms 11Carcinoma, Transitional Cell 11Lymphoma, Large B-Cell, Diffuse 10Gallbladder Neoplasms 9Adenocarcinoma Of Esophagus 9

Interventions

Tenofovir 5entecavir 3peginterferon alfa-2b 2peginterferon alfa-2a 1ibrutinib 1durvalumab 1babao dan 1Radiofrequency Ablation 1Observation 1Nucleosides 1Methods 1Interferons 1Cholecalciferol 1Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hepatitis B, Chronic × durvalumab × Clear all
NCT04294498 2025-03-26

Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection

National Taiwan University Hospital

Phase 2 Active not recruiting
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Hepatitis B, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡